> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# DESI Update: Anticholinergic/Antispasmodic Combo Products
- URL: https://www.fdaweb.com/desi-update-anticholinergic-antispasmodic-combo-products/
- Published: 2022-04-26T12:00:00.000Z
- Updated: 2026-09-14T17:42:09.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151680

*Federal Register* notice: FDA is announcing that all outstanding hearing requests regarding drug products containing an anticholinergic or antispasmodic in combination with a sedative, and single-entity antispasmodic drug products, in oral dosage form, under Docket FDA-1975-N-0336 (formerly 75N–0184) have been withdrawn. Therefore, shipment in interstate commerce of any such product identified in the docket covered by Drug Efficacy Study Implementation (DESI) 10837, or any identical, related, or similar product, that is not the subject of an approved NDA/ANDA is now unlawful. The notice does not affect products covered by DESI 597 under the same docket. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-04-25/pdf/2022-08740.pdf?ref=fdaweb.com).